A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Trial Profile

A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Alprazolam (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms StATES
  • Sponsors Engage Therapeutics
  • Most Recent Events

    • 07 May 2018 According to an Engage Therapeutics media release, first patient has been dosed, and topline data is expected in the second half of 2019.
    • 20 Mar 2018 Status changed from planning to recruiting.
    • 04 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top